Cannabis in Personalized Wellness Plans: What the Evidence Supports, and What It Doesn’t
Cannabis may have a place in individualized care, but its potential is narrower—and its risks more significant—than many wellness claims suggest. The effects of cannabis products vary according to their cannabinoid content, dose, route of administration, product quality, other medications, and the individual’s health history. A personalized approach therefore requires medical guidance and realistic expectations rather than relying on strain names or broad claims about “natural” therapy.
The cannabis plant contains numerous compounds, including the cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is intoxicating and can affect memory, coordination, judgment, and reaction time. CBD is not generally intoxicating, but it is not risk-free: the U.S. Food and Drug Administration’s overview of cannabis- and CBD-derived products notes potential concerns including liver injury, drowsiness, gastrointestinal effects, and interactions with other medications.
Evidence for therapeutic use is strongest for a limited number of applications. The National Academies’ review of the health effects of cannabis and cannabinoids found substantial or conclusive evidence of benefit in some circumstances, including chronic pain in adults, chemotherapy-related nausea and vomiting, and patient-reported spasticity symptoms associated with multiple sclerosis. These findings do not establish cannabis as a general treatment for pain, anxiety, depression, PTSD, or other complex conditions.
In fact, the evidence for pain relief remains mixed. After reviewing clinical and preclinical research, the International Association for the Study of Pain concluded that there was not enough high-quality evidence to endorse the general use of cannabis or cannabinoids for pain. Any decision to try a cannabinoid product should take into account the underlying condition, alternatives with stronger evidence, likely benefits, and possible harms.
Why personalization matters
People can respond very differently to the same product. Relevant factors include age, pregnancy or breastfeeding status, cardiovascular and psychiatric history, liver function, prior experience with cannabis, and the medications or supplements a person already takes. CBD and THC may alter the effects of other drugs, making a review by a physician or pharmacist especially important for people receiving treatment for chronic conditions.
Product labels also require caution. Terms such as “indica,” “sativa,” and strain names do not reliably communicate a product’s chemical composition or predict its effects. A more useful approach is to examine the stated amounts of THC and CBD, serving size, route of administration, and independent laboratory testing when available. Claims about an “entourage effect”—the idea that cannabinoids and terpenes work together to produce superior results—remain an area of investigation rather than a settled basis for prescribing specific combinations.
Route of administration changes the experience
Inhaled cannabis generally acts more quickly than oral products, but smoking exposes the lungs to harmful compounds and vaping carries its own risks. Edibles and other oral products can take longer to produce noticeable effects, which may lead people to consume more before the first dose has taken effect. This delayed onset can increase the risk of unwanted intoxication.
Topical products are often marketed for localized discomfort, but evidence for many over-the-counter cannabis creams and lotions is limited. Consumers should not assume that a product’s route of administration makes it effective or risk-free. Starting with the lowest labeled amount, avoiding rapid redosing, and stopping if significant side effects occur are prudent harm-reduction measures—but they do not replace professional advice.
Safety and legal considerations
Legal availability does not mean that a product is proven safe or effective. In the United States, the FDA has approved one prescription CBD medicine for certain severe seizure disorders and several cannabis-related prescription medicines for specific indications. Most cannabis and CBD products sold through dispensaries, stores, or online marketplaces have not undergone the FDA’s review for effectiveness, dosage, purity, or drug interactions.
Regulated-market products may provide more information about potency and contaminants than unregulated products, but testing and labeling standards vary by jurisdiction. Consumers should check local requirements and avoid products making unsupported claims to treat serious diseases.
Some people should avoid cannabis or seek medical advice before using it. The FDA strongly advises against using CBD, THC, or marijuana during pregnancy or breastfeeding; its guidance is available in this safety information for pregnant and breastfeeding individuals. Cannabis can also impair driving and coordination. The Centers for Disease Control and Prevention’s guidance on cannabis and driving recommends not driving after using cannabis and warns that combining it with alcohol can increase impairment.
A responsible personalized wellness plan should begin with a clearly defined health goal and an assessment of safer, better-supported treatments. If cannabis is considered, a clinician or pharmacist can help evaluate the product, dose, interactions, side effects, and plan for monitoring its effects. Cannabis may benefit some patients in specific circumstances, but current evidence does not support presenting it as a universal solution for personalized wellness.
